Stockscreener 앱 받기
2.8982
0.52%
0.0082
Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스
FY2025 EPS Estimates for TSHA Lifted by Cantor Fitzgerald - Defense World
Taysha, FDA agree on next steps of REVEAL trial for Rett gene therapy - Rett Syndrome News
Taysha outlines expedited pivotal trial start for TSHA-102 following FDA alignment - MSN
Canaccord Genuity Group Forecasts Strong Price Appreciation for Taysha Gene Therapies (NASDAQ:TSHA) Stock - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 6.1% Following Analyst Upgrade - Defense World
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates - MSN
Expert Outlook: Taysha Gene Therapies Through The Eyes Of 6 Analysts - Benzinga
Taysha Gene Therapies (TSHA) Sees Price Target Raised by Canaccord Genuity | TSHA Stock News - GuruFocus
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2025 Earnings Call Transcript - Insider Monkey
Canaccord Boosts Price Target for Taysha Gene Therapies (TSHA) | - GuruFocus
Taysha Gene Therapies Reports First Quarter 2025 Financial Resul - GuruFocus
Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Call Highlights: Promising Clinical Progress ... - Yahoo Finance
Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Call Highlight - GuruFocus
Taysha Gene Therapies Advances in Rett Syndrome Trials - TipRanks
Baird maintains Outperform on Taysha stock, reiterates $7 target By Investing.com - Investing.com Nigeria
Transcript : Taysha Gene Therapies, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Taysha Gene Therapies’ Positive Q1 2025 Earnings Call - TipRanks
Baird maintains Outperform on Taysha stock, reiterates $7 target - Investing.com
Earnings call transcript: Taysha Gene Therapies Q1 2025 sees stock surge on earnings beat - Investing.com Nigeria
Taysha Gene Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Taysha Gene Therapies Q1 2025 Earnings Call Transcript - MarketBeat
Taysha (TSHA) Q1 Revenue Exceeds Expectations, Progresses with C - GuruFocus
Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Taysha (TSHA) Q1 Revenue Exceeds Expectations, Progresses with Clinical Trials | TSHA Stock News - GuruFocus
Taysha Gene Therapies Q1 2025 Financial Results - TradingView
Taysha's Rett Syndrome Gene Therapy Gains FDA Support: Key Trial Design Approved Without Phase Meeting - Stock Titan
Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Acquired by Hsbc Holdings PLC - Defense World
Taysha Gene Therapies (TSHA) to Release Quarterly Earnings on Thursday - Defense World
Wells Fargo & Company MN Has $179,000 Stock Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Barclays PLC Grows Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Mariner LLC Has $101,000 Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15 - The Manila Times
Taysha Gene Therapies to Release First Quarter 2025 - GlobeNewswire
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know - MSN
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Benzinga
Taysha Gene Therapies Inc (NASDAQ: TSHA) Up 40.46% This Year: What To Expect Next - Stocksregister
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 9.3% – Should You Buy? - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Price Target from Analysts - Defense World
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Taysha Gene Therapies (TSHA) Grants Employee Stock Option Under Inducement Plan | TSHA Stock News - GuruFocus
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Li - GuruFocus
BMO Capital Markets slashes price target on Taysha Gene Therapies Inc [TSHA] – find out why. - dbtnews.com
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | TSHA Stock News - GuruFocus
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies (TSHA) Gains Analyst Support with Promising Gene Therapy | TSHA Stock News - GuruFocus
Buying Buzz: Taysha Gene Therapies Inc [TSHA] 10% Owner Manning Paul B purchases 1,333,333 shares of the company – Knox Daily - knoxdaily.com
Anchoring Your Portfolio: Is TSHA Stock a Safe Harbor? - investchronicle.com
60,000 Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Bought by LPL Financial LLC - Defense World
1.40%
8.08%
자본화:
|
볼륨(24시간):